WO2002067866A3 - Piperazine derivatives as metalloprotease inhibitors - Google Patents

Piperazine derivatives as metalloprotease inhibitors Download PDF

Info

Publication number
WO2002067866A3
WO2002067866A3 PCT/US2002/005996 US0205996W WO02067866A3 WO 2002067866 A3 WO2002067866 A3 WO 2002067866A3 US 0205996 W US0205996 W US 0205996W WO 02067866 A3 WO02067866 A3 WO 02067866A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperazine derivatives
metalloprotease inhibitors
formula
compounds
inhibitors
Prior art date
Application number
PCT/US2002/005996
Other languages
French (fr)
Other versions
WO2002067866A2 (en
Inventor
Jeffrey Mark Dener
Original Assignee
Axys Pharm Inc
Jeffrey Mark Dener
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc, Jeffrey Mark Dener filed Critical Axys Pharm Inc
Priority to AU2002255613A priority Critical patent/AU2002255613A1/en
Publication of WO2002067866A2 publication Critical patent/WO2002067866A2/en
Publication of WO2002067866A3 publication Critical patent/WO2002067866A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel compounds of Formula (I), pharmaceutically acceptable salts and N-oxides thereof, which are useful as MatriX Metalloprotease (MMP) inhibitors. Also included in the present invention is the method fo using compounds of Formula (I) and therapeutic use of the compounds of Formula (I).
PCT/US2002/005996 2001-02-27 2002-02-27 Piperazine derivatives as metalloprotease inhibitors WO2002067866A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002255613A AU2002255613A1 (en) 2001-02-27 2002-02-27 Piperazine derivatives as metalloprotease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27182101P 2001-02-27 2001-02-27
US60/271,821 2001-02-27

Publications (2)

Publication Number Publication Date
WO2002067866A2 WO2002067866A2 (en) 2002-09-06
WO2002067866A3 true WO2002067866A3 (en) 2003-05-01

Family

ID=23037231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005996 WO2002067866A2 (en) 2001-02-27 2002-02-27 Piperazine derivatives as metalloprotease inhibitors

Country Status (2)

Country Link
AU (1) AU2002255613A1 (en)
WO (1) WO2002067866A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
WO2003106381A2 (en) 2002-06-12 2003-12-24 Exelixis, Inc. Human adam-10 inhibitors
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008825A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company 1,4-heterocyclic metalloprotease inhibitors
WO1998027069A1 (en) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008825A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company 1,4-heterocyclic metalloprotease inhibitors
WO1998027069A1 (en) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENG M ET AL: "DESIGN AND SYNTHESIS OF PIPERAZINE-BASED MATRIX METALLOPROTEINASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 3, 2000, pages 369 - 380, XP000919159, ISSN: 0022-2623 *
O'BRIEN ET AL.: "Structure-Activity Relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulphonamide matrix metalloproteinase inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 2, 2000, pages 156 - 166, XP002214476 *

Also Published As

Publication number Publication date
WO2002067866A2 (en) 2002-09-06
AU2002255613A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
ATE394383T1 (en) BIPHENYL CARBONIC ACID AMIDE DERIVATIVES AS P38 KINASE INHIBITORS
GB9801690D0 (en) Therapeutic agents
NO20061157L (en) 4-pyramidone derivatives and their use as peptidyl peptide inhibitors
NO20051695L (en) Novel spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
ES2195785A1 (en) Pyridazin-3(2h)-one derivatives as pde4 inhibitors
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
WO2004056827A3 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
DE60316013D1 (en) HETEROARYL PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
NO20066055L (en) pyridine derivatives
SE0202463D0 (en) Novel compounds
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
MXPA03010961A (en) Thiazole compounds useful as inhibitors of protein kinases.
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
WO2002096905A8 (en) Thiazole compounds useful as inhibitors of protein kinases
EP1248612A4 (en) Novel compounds and compositions as protease inhibitors
CA2441313A1 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2002246728A1 (en) Carboline derivatives
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2004100865A3 (en) New benzimidazole derivatives
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
AU2002249890A1 (en) Carboline derivatives
AU2003250471A1 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP